Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAFE-AF: Low-dose vs Standard-dose Rivaroxaban in Elderly AF
NCT06108414Phase 4Recruiting
- Sponsor
- National Center for Cardiovascular Disease
- Start
- Sep 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of rivaroxaban in Atrial fibrillation (AFib) (2 arms), sponsored by National Center for Cardiovascular Disease. Primary endpoint: Major Adverse Cardiovascular and Cerebrovascular Events at 2 years. Started Sep 2024; status: recruiting.
02
Drugs
rivaroxaban
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT06108414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06108414.